Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Trial Profile

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 03 Aug 2017 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
    • 09 May 2017 According to a Neurocrine Biosciences media release, the Company announced that in July 2017 it plans to complete this roll-over study.
    • 10 Oct 2016 Planned number of patients changed from 75 to 150.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top